Learn about AJOVY® (fremanezumab-vfrm) injection
AJOVY is available in an autoinjector. It can be administered in office or at home.
To take a deeper dive into the pharmacokinetic profile, half-life, clinical trials data, or dosing options of AJOVY, download the brochures below or visit our website.
*”Long-acting” defined as efficacy measured over a 12-week period following a 675 mg (225 mg x 3) SC dose.
†Quarterly dosing 675 mg (225 mg x 3) SC. Also available in monthly dosing 225 mg SC.
AJOVY is indicated for the preventive treatment of migraine in adults.
IMPORTANT SAFETY INFORMATION
Contraindications: AJOVY is contraindicated in patients with serious hypersensitivity to fremanezumab-vfrm or to any of the excipients.
Hypersensitivity Reactions: Hypersensitivity reactions, including rash, pruritus, drug hypersensitivity, and urticaria were reported with AJOVY in clinical trials. Most reactions were mild to moderate, but some led to discontinuation or required corticosteroid treatment. Most reactions were reported from within hours to one month after administration. If a hypersensitivity reaction occurs, consider discontinuing AJOVY and institute appropriate therapy.
Adverse Reactions: The most common adverse reactions (≥5% and greater than placebo) were injection site reactions.
See the full Prescribing Information (PI) below.
CGRP: calcitonin gene-related peptide; SC: Subcutaneous
Reference: 1. AJOVY® (fremanezumab-vfrm) injection Current Prescribing Information. North Wales, PA: Teva Pharmaceuticals USA, Inc.
FRE-43068 September 2020